$SCTX

$15.60 +$0.20 (1.27%) Close

$SCTX Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Ownership

13F as of Q2 2026 · 18.9M shares outstanding

Who owns SCTX?

By type of holder

Institutions 0.0% Insiders 44.9% Everyone else 55.1%

Concentration Top 10 holders own 70.0%

Aghazadeh Behzad 16.3% · Avoro Capital Advisors LLC 13.7%

Institutional ownership

0.0%

0.0 pts vs last qtr

Institutional holders

0 vs last qtr

Net shares bought

by institutions in Q2 2026

New / sold out

0 / 0

positions opened vs closed

How is ownership changing?

Institutions, last 8 quarters

No 13F manager has reported this stock in the last 8 quarters.

Biggest buyers in Q2 2026

None.

Biggest sellers in Q2 2026

None.

Who is planning to sell?

No insider has filed a notice of proposed sale (Form 144) for Scribe Therapeutics Inc in the last 12 months.

Is your stake being diluted?

There are not yet two fiscal years of reported share counts for Scribe Therapeutics Inc.

How patient are the owners?

No 13F manager reports holding SCTX.

Super Investors

Investment managers reporting SCTX on Form 13F

No 13F manager reports holding SCTX yet.

Institutional Funds

Mutual funds and ETFs reporting SCTX on Form N-PORT; together they hold 2.6% of the company

Fund	Position value	Shares	% of company	% of the fund	As of
AG ARK Genomic Revolution ETF ARK ETF Trust	$6.86M	352.1K	1.86%	0.44%	July 31, 2026
FB Franklin Biotechnology Discovery Fund Franklin Strategic Series	$2.64M	135.6K	0.72%	0.23%	July 31, 2026

ARK Genomic Revolution ETF

ARK ETF Trust

Position value

$6.86M

% of company

1.86%

% of the fund

0.44%

As of

July 31, 2026

Franklin Biotechnology Discovery Fund

Franklin Strategic Series

Position value

$2.64M

% of company

0.72%

% of the fund

0.23%

As of

July 31, 2026

Insiders and 5%+ holders

From Forms 3/4/5 and Schedules 13D/G

Holder	Shares	% of company	Change vs last qtr	8 quarters	Held since	% of their book
AB Aghazadeh Behzad 5%+ holder 13D · 16.4%	3.1M	16.32%	—	—	—	—
This holder reports through Schedule 13D/G, not a quarterly 13F. Share of the company16.320% Disclosed stake13D · 16.4% View the 13D/G filing →
AC Avoro Capital Advisors LLC 5%+ holder 13D · 13.8%	2.6M	13.73%	—	—	—	—
This holder reports through Schedule 13D/G, not a quarterly 13F. Share of the company13.730% Disclosed stake13D · 13.8% View the 13D/G filing →

Aghazadeh Behzad

5%+ holder13D · 16.4%

3.1M

% of company

16.32%

Change vs last qtr

—

Held since

—

Avoro Capital Advisors LLC

5%+ holder13D · 13.8%

2.6M

% of company

13.73%

Change vs last qtr

—

Held since

—

10 more holders behind a free account

See every insider and 5%+ holder of Scribe Therapeutics Inc.

Comments